Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: A randomized, double-blind, placebo-controlled study of efficacy and tolerability

Pediatric Blood and Cancer

Volumn 52, Issue 2, 2009, Pages 242-247

  Gore, Lia ^a,e   Chawla, Sant ^b   Petrilli, Antonio ^c   Hemenway, Molly ^a   Schissel, Debra ^a   Chua, Vickey ^b   Carides, Alexandra D ^d   Taylor, Arlene ^d   DeVandry, Suzanne ^d   Valentine, Jack ^d   Evans, Judith K ^d   Oxenius, Bettina ^d  

^a CHILDREN S HOSPITAL COLORADO   (United States)

^b Sarcoma Oncology Center   (United States)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d MERCK RESEARCH LABORATORIES   (United States)

^e UNIVERSITY OF COLORADO   (United States)

Author keywords

Adolescent; Antiemetic; Aprepitant; Nausea and vomiting; NK1 antagonist; Supportive care

Indexed keywords

APREPITANT; DEXAMETHASONE; ONDANSETRON; PLACEBO; ANTINEOPLASTIC AGENT; MORPHOLINE DERIVATIVE;

ADOLESCENT; ADULT; ADVERSE OUTCOME; AREA UNDER THE CURVE; ARTICLE; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HICCUP; HUMAN; HYPOKALEMIA; LEUKOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA AND VOMITING; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; CHEMICALLY INDUCED DISORDER; DRUG TOXICITY; METABOLIC CLEARANCE RATE; NAUSEA; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CHILD; DEXAMETHASONE; DOUBLE-BLIND METHOD; DRUG TOXICITY; HUMANS; METABOLIC CLEARANCE RATE; MORPHOLINES; NAUSEA; NEUTROPENIA; ONDANSETRON; PLACEBOS; TREATMENT OUTCOME; VOMITING; YOUNG ADULT;

EID: 59349121894     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21811     Document Type: Article

References (10)

1. Jordan K, Sippel C, Schmoll H. Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: Past, present, and future recommendations. Oncologist 2007;12:1143-1150.
2. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update2006. J Clin Oncol 2006;24:2932-2947.
3. Roila F, Hesketh PJ, Herrstedt J, et al. Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the 2004 Perugia international antiemetic consensus conference. Ann Oncol 2006;17:20-28.
4. EMEND® capsules (Merck) (aprepitant). U.S. [Package Insert]. 2006.
5. de Wit R, Hesketh PJ, Warr D, et al. The oral NK1 antagonist aprepitant for prevention of nausea and vomiting in patients receiving highly emetogenic chemotherapy: A review. Am J Cancer 2005;4:35-48.
6. Chavez-Eng CM, Constanzer ML, Matuszewski BK. Simultaneous determination of aprepitant and two metabolites in human plasma by high-performance liquid chromatography with tandem mass spectrometric detection. J Pharm Biomed Anal 2004;35:1213-1229.
7. Chan I, Zhang Z. Test based exact confidence intervals for the difference of two binomial proportions. Biometrics 1999;55:1201-1209.
8. Depre M, Van Hecken A, Oeyen M, et al. Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. Eur J Clin Pharmacol 2005;61:341-346.
9. Steel RGD, Torrie JH. Principles and procedures of statistics, 2nd edition. New York: McGraw Hill Book Company; 1980.
10. ASHP Commission on Therapeutics. ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm 1999;56:729-764.